Opportunity Information: Apply for PA 16 039
Apply for PA 16 039
- The HHS-NIH11 in the food and nutrition, health sector is offering a public funding opportunity titled "Advancing Erythroid Cell Biology (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.839, 93.847,.
- This funding opportunity was created on Nov 20, 2015 and posted on Nov 20, 2015.
- Applicants must submit their applications by Jan 07, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Advancing Erythroid Cell Biology (R01) opportunity (PA-16-039) is a National Institutes of Health (NIH) research grant announcement that supports investigator-initiated, hypothesis-driven studies focused on erythroid cells and the process of erythropoiesis, meaning the development and maturation of red blood cells. The central purpose is to push the field toward a more complete, integrated understanding of the molecular and cellular machinery that produces normal red blood cell formation, with the broader clinical motivation of improving how anemia is measured, understood, and ultimately treated.
Research proposed under this FOA is expected to dig into the core components that define erythroid biology across development and differentiation. It specifically highlights multi-layer "omics" and mechanistic work that clarifies how erythropoiesis is controlled and executed. This includes the erythroid transcriptome (which genes are turned on and off at particular stages or in particular erythroid populations), the erythroid epigenome (chemical modifications to DNA and histone proteins that influence gene regulation and cell fate decisions), and the erythroid proteome (which proteins are produced, how they are modified after translation, and where they localize within the cell). The emphasis is not just on cataloging these components, but on explaining how they function together to produce normal erythroid maturation and physiology.
A longer-range objective of the program is to help build a coherent, streamlined description of erythropoiesis that ties together genetics, molecular processes, and cytokine-driven determinants within erythroid lineages. In practical terms, NIH is looking for projects that can connect regulatory mechanisms (such as gene networks and epigenetic control points) with signaling inputs and cellular outputs in a way that clarifies why erythropoiesis succeeds in healthy settings and fails in disease. By supporting that kind of unifying framework, the program aims to lay groundwork for therapeutics and diagnostic approaches that can better address anemia, whether by identifying new targets, improving biomarkers, or revealing key stages where interventions could restore normal red blood cell production.
This is an R01 mechanism, meaning it is intended for substantial, independent research projects where the applicant proposes the scientific direction and experimental plan. The opportunity is categorized as discretionary and falls under health-related funding activity categories (CFDA 93.839 and 93.847). Eligibility is broad and includes many types of U.S.-based entities such as state, county, and local governments; public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; federally recognized tribal governments and other eligible tribal organizations; public housing authorities/Indian housing authorities; for-profit organizations (other than small businesses); small businesses; and other applicants as allowed by NIH policy and any additional eligibility clarifications referenced in the full announcement. The sponsoring agency is within the U.S. Department of Health and Human Services, National Institutes of Health.
Key administrative details in the posted record include a creation and posting date of November 20, 2015, and a listed closing date of January 7, 2019 (with the same date shown as both original and current in the provided source information). The listing does not provide an award ceiling or an expected number of awards in the fields shown, so those specifics would typically be determined by NIH institute budgets, application volume, and scientific merit, and may be clarified in the full FOA text or related NIH notices.
Frequently Asked Questions (FAQs): Advancing Erythroid Cell Biology (R01) - PA-16-039
What is the Advancing Erythroid Cell Biology (R01) opportunity (PA-16-039)?
PA-16-039 is a National Institutes of Health (NIH) research grant announcement that supports investigator-initiated, hypothesis-driven R01 studies focused on erythroid cells and erythropoiesis (the development and maturation of red blood cells). The program is designed to advance a more complete, integrated understanding of the molecular and cellular machinery that drives normal red blood cell formation, with a broader clinical motivation tied to improving how anemia is measured, understood, and treated.
What is the main purpose of this funding opportunity?
The central purpose is to push the field toward a more comprehensive and integrated description of erythropoiesis. NIH is looking for research that explains how key molecular and cellular components work together to produce normal erythroid maturation and physiology, and that helps clarify why erythropoiesis succeeds in healthy settings and fails in disease.
What scientific areas does this FOA focus on?
This opportunity focuses on core erythroid biology across development and differentiation, including the mechanisms that control and execute erythropoiesis. It highlights multi-layer "omics" and mechanistic work aimed at clarifying the molecular and cellular machinery that underlies normal red blood cell formation.
What does "erythropoiesis" mean in the context of this announcement?
In this announcement, erythropoiesis refers to the development and maturation of red blood cells, including the developmental and differentiation processes within erythroid lineages that result in normal red blood cell production and function.
What types of "omics" are specifically highlighted?
The announcement specifically highlights three interconnected "omics" areas within erythroid biology: the erythroid transcriptome, the erythroid epigenome, and the erythroid proteome. The emphasis is on using these layers to understand how erythropoiesis is controlled and executed.
What is meant by the erythroid transcriptome in this FOA?
The erythroid transcriptome is described as which genes are turned on and off at particular stages or in particular erythroid populations. Projects may focus on how gene expression programs change as erythroid cells develop and mature.
What is meant by the erythroid epigenome in this FOA?
The erythroid epigenome is described as chemical modifications to DNA and histone proteins that influence gene regulation and cell fate decisions. The FOA emphasizes understanding how these modifications shape erythroid differentiation and maturation.
What is meant by the erythroid proteome in this FOA?
The erythroid proteome is described as which proteins are produced, how they are modified after translation, and where they localize within the cell. Research may examine how protein production, modification, and localization contribute to normal erythroid maturation and physiology.
Is the FOA focused on generating catalogs of omics data, or on mechanisms?
The emphasis is not just on cataloging components. The FOA highlights mechanistic work that explains how transcriptomic, epigenomic, and proteomic components function together to produce normal erythroid maturation and physiology.
What does NIH mean by a "more complete, integrated understanding" of erythropoiesis?
Based on the description provided, the program aims to tie together multiple layers of biology (genetics, molecular processes, and cytokine-driven determinants) into a coherent and streamlined description of erythropoiesis within erythroid lineages. The goal is a unifying framework that connects regulatory mechanisms with signaling inputs and cellular outputs.
What kinds of regulatory mechanisms are mentioned?
The opportunity references regulatory mechanisms such as gene networks and epigenetic control points. Projects are expected to connect these regulatory features to signaling inputs and the resulting cellular outcomes relevant to erythroid development and maturation.
What is the longer-range objective of the program?
A longer-range objective is to help build a coherent, streamlined description of erythropoiesis that connects genetics, molecular processes, and cytokine-driven determinants within erythroid lineages. This is intended to support a clearer understanding of normal erythropoiesis and its failure in disease.
How is this FOA connected to anemia research and clinical impact?
The broader clinical motivation is to improve how anemia is measured, understood, and treated. By building a more integrated understanding of erythropoiesis and identifying key regulatory and mechanistic points, the program aims to lay groundwork for improved therapeutics and diagnostics, including new targets, improved biomarkers, or identifying stages where interventions could restore normal red blood cell production.
What is the funding mechanism for this opportunity?
This is an R01 mechanism. It is intended for substantial, independent research projects in which the applicant proposes the scientific direction and experimental plan (investigator-initiated, hypothesis-driven research).
Who is the sponsoring agency?
The sponsoring agency is within the U.S. Department of Health and Human Services, National Institutes of Health (NIH).
What funding activity categories and CFDA numbers are associated with this opportunity?
The opportunity is categorized as discretionary and falls under health-related funding activity categories. The CFDA numbers listed are 93.839 and 93.847.
What types of organizations are eligible to apply?
Eligibility is broad and includes many types of U.S.-based entities, including: state, county, and local governments; public and private institutions of higher education; nonprofit organizations with or without 501(c)(3) status; federally recognized tribal governments and other eligible tribal organizations; public housing authorities/Indian housing authorities; for-profit organizations (other than small businesses); small businesses; and other applicants as allowed by NIH policy and any additional eligibility clarifications referenced in the full announcement.
Are for-profit organizations eligible?
Yes. The eligibility list includes for-profit organizations (other than small businesses) and also includes small businesses.
Are tribal governments and tribal organizations eligible?
Yes. The eligibility list includes federally recognized tribal governments as well as other eligible tribal organizations.
Are public housing authorities eligible?
Yes. The eligibility list includes public housing authorities/Indian housing authorities.
Does the provided listing include an award ceiling?
No. The posted record does not provide an award ceiling in the fields shown.
Does the provided listing include the expected number of awards?
No. The posted record does not provide an expected number of awards in the fields shown.
If the award ceiling and number of awards are not listed, how are they typically determined?
Based on the information provided, those specifics would typically be determined by NIH institute budgets, application volume, and scientific merit, and may be clarified in the full FOA text or related NIH notices.
What are the key posted administrative dates for this opportunity?
The posted record includes a creation and posting date of November 20, 2015. It also lists a closing date of January 7, 2019, with the same date shown as both the original and current closing date in the provided source information.
What kind of research approach does NIH appear to be encouraging?
The description emphasizes investigator-initiated, hypothesis-driven projects that combine multi-layer omics with mechanistic studies. The intent is to connect regulatory mechanisms (for example, gene networks and epigenetic control points) to signaling inputs and measurable cellular outputs in erythroid lineages.
What would be considered a strong alignment with the FOA based on the description provided?
Strong alignment would involve research that goes beyond describing components and instead explains how transcriptomic, epigenomic, and proteomic layers integrate to drive normal erythroid maturation. The FOA also emphasizes building a unifying framework that links genetics, molecular processes, and cytokine-driven determinants to outcomes relevant to healthy erythropoiesis and disease failure states, with relevance to anemia measurement, understanding, and treatment.
Browse more opportunities from the same category: Food and Nutrition, Health
Next opportunity: Watershed disturbance and restoration impacts on hydrologic function: Model calibration and validation on a landscape scale
Previous opportunity: BRAIN Initiative: Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 16 039
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 16 039) also looked into and applied for these:
| Funding Opportunity |
|---|
| SBIR/STTR Commercialization Readiness Pilot (CRP) Program: Technical Assistance and Late Stage Development (SB1) Apply for PAR 16 027 Funding Number: PAR 16 027 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Understanding Barriers and Facilitators to Type 1 Diabetes Management in Adults (DP3) Apply for RFA DK 16 002 Funding Number: RFA DK 16 002 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $2,500,000 |
| Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01) Apply for RFA DK 16 014 Funding Number: RFA DK 16 014 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Innovative Research in HIV in Kidney, Urology, and Hematology (R01) Apply for RFA DK 16 015 Funding Number: RFA DK 16 015 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $500,000 |
| George M. O'Brien Urology Cooperative Research Centers Program (U54) Apply for RFA DK 16 013 Funding Number: RFA DK 16 013 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $1,000,000 |
| Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44) Apply for RFA DK 16 004 Funding Number: RFA DK 16 004 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Psychosocial and Behavioral Mechanisms in Bariatric Surgery (R01) Apply for RFA DK 16 017 Funding Number: RFA DK 16 017 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $500,000 |
| Small Grants for New Investigators to Promote Diversity in Health-Related Research (R21) Apply for PAR 16 064 Funding Number: PAR 16 064 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $125,000 |
| Limited Competition for the Continuation of the Scientific Data Research Center (SDRC) for the NIDDK Gastroparesis Consortium (U24) Apply for RFA DK 16 507 Funding Number: RFA DK 16 507 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $1,000,000 |
| Clinical Centers to Investigate the Pathogenesis, Etiology, and Treatment of Gastroparesis through the NIDDK Gastroparesis Consortium (U01) Apply for RFA DK 16 010 Funding Number: RFA DK 16 010 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $250,000 |
| Silvio O. Conte Digestive Diseases Research Core Centers (P30) Apply for RFA DK 16 019 Funding Number: RFA DK 16 019 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $750,000 |
| NIDDK Program Projects (P01) Apply for PAR 16 127 Funding Number: PAR 16 127 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $6,250,000 |
| High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2) Apply for PAR 16 126 Funding Number: PAR 16 126 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01) Apply for PAR 16 121 Funding Number: PAR 16 121 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Limited Competition: Small Grant Program for NIDDK K01/K08/K23 Recipients (R03) Apply for PAR 16 148 Funding Number: PAR 16 148 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $50,000 |
| Advances in Polycystic Kidney Disease (R01) Apply for PA 16 159 Funding Number: PA 16 159 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| Human Islet Distribution Coordinating Center (UC4) Apply for RFA DK 16 023 Funding Number: RFA DK 16 023 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: $1,300,000 |
| Limited Competition: Rare Diseases Clinical Research Network (RDCRN) Project Supplements for Clinical Trials to Repurpose Drugs in Collaboration with E-Rare Awardees (Admin Supp) Apply for PA 16 183 Funding Number: PA 16 183 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| NIDDK Short-Term Research Experience Program for Underrepresented Persons (STEP-UP) (R25) Apply for RFA DK 16 021 Funding Number: RFA DK 16 021 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
| NIDDK Mentored Research Scientist Development Award (K01) Apply for PAR 16 211 Funding Number: PAR 16 211 Agency: HHS-NIH11 Category: Food and Nutrition, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants

Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 16 039", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
